The non patent eligibility of a new dosage for the same disease was reiterated by a decision issued by the tribunal de grande instance de Paris, 3rd chamber, 3rd section, handed down on 5 December 2014 in the infringement proceedings between Akzo Nobel NV, MSD OSS BV and MSD France SAS, on the one hand, and Teva Santé SAS, Ratiopharm GmbH, Merckle GmbH and Cemelog-BRS Ltd, on the other hand.
Teva was sued for launching a generic of the reference drug Cerazette a few months before the expiry of MSD’s supplementary protection certificate based on European patent № 0 491 443 relating to a contraceptive preparation containing progestogen only, more precisely desogestrel, 3-ketodesoges [...]
On 23 September 2014, the cour d’appel de Paris, in Genentech v. Hoechst and Sanofi Aventis Deutschland, Docket № 12/21810, decided to refer to the Court of Justice of the European Union the following question:
“Should the provisions of Article 81 of the Treaty, now Article 101 of the Treaty on the Functioning of the European Union, be interpreted as an obstacle to giving effect, in case of invalidation of the patents, to a licence agreement which imposes on the licensee royalties for the sole use of the rights attached to the patents under licence?”
Through this referral the court questions the compatibility [...]
Tribunal de grande instance de Paris, 3rd chamber, 1st section, 3 July 2014, Evinerude v. Philippe Giraudeau and Aair Lichens
While the US decisions in Mayo Collaborative Services v. Prometheus Laboratories Inc. and Myriad Genetics led the USPTO to issue new guidelines to the attention of examiners on the procedure for subject matter eligibility analysis of claims reciting or involving “interalia” laws of nature and natural products, the tribunal de grande instance de Paris, in a judgment of 3 July 2014, clarifies the exclusion of discoveries from patent-eligible subject matter.
1. Presentation of the judgment
Philippe Giraudeau is the inventor and the applicant of [...]
Reports that say there’s — that something hasn’t happened are always interesting to me, because as we know, there are known knowns; there are things that we know that we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns, the ones we don’t know we don’t know.
Donald Rumsfeld, United States Secretary of Defense, 1975-1977 and 2001-2006
According to Article 89 of the Agreement on a Unified Patent Court (UPCA), the Agreement is set up to enter into force on one of three dates, whichever is the latest. The first date provided in the Agreement was 1 January 2014. As we all know, it did not h [...]
Until recently, third parties had not to worry about the date at which they would initiate a patent revocation action in France. However, nowadays, this issue is a hot topic in France.
The origin of the current controversy is not recent as it lies in statute № 2008-561 of 17 June 2008 which shortened to 5 years the time limit to initiate actions qualified, under French law classification, as personal actions or real actions based on movable assets. This 5-year time period runs from the date at which the owner of a right becomes aware or should have been aware of the facts entitling him to do so.
For the time being, only one decision had the opportunity to decide upon the determination of [...]
The French Supreme Court condemned a patentee’s undue use of an evidentiary measure (infringement seizure, “saisie-contrefaçon”) as a way to obtain information from a competitor, specifically information relating to the manufacturing processes of its direct competitor, beyond the scope of the lawsuit (“fishing expedition”).